PALLD and pancreatic adenocarcinoma: Twenty-eight members from Family X were available for mutational testing of palladin: 12 individuals with pancreatic adenocarcinoma (n = 3) or histologically verified precancerous dysplasia (n = 9) and 16 unaffected individuals.